Concentric Capital Strategies »

Apellis Pharmaceuticals shares owned by Concentric Capital Strategies

Quarter-by-quarter ownership of Apellis Pharmaceuticals (APLS) shares owned by Concentric Capital Strategies from 13F filings

Historical chart of Concentric Capital Strategies investment in Apellis Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Apellis Pharmaceuticals held by Concentric Capital Strategies consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Apellis Pharmaceuticals by Concentric Capital Strategies

Quarter filed Position value Share count Share price at filing
2025-09-30 $407k 18k 22.63

More positions owned by Concentric Capital Strategies

Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Kellogg Company Put Option (K)
Potlatch Corporation Call Option (PCH)
Microsoft Corporation (MSFT)
Packaging Corporation of America (PKG)
Apple (AAPL)
Rayonier Call Option (RYN)
Madison Square Grdn Sprt Cor Cl A (MSGS)
Steel Dynamics (STLD)
Amazon (AMZN)
L3harris Technologies (LHX)
WESCO International (WCC)
Coinbase Global Com Cl A (COIN)
NVIDIA Corporation (NVDA)
Meta Platforms Cl A (META)

View all positions for Concentric Capital Strategies

Top funds holding Apellis Pharmaceuticals

venBio Select Advisor
Vanguard Group
Morgan Stanley
Wellington Management Company
Deep Track Capital
BlackRock
AQR Capital Management
Jennison Associates
State Street Corporation
EcoR1 Capital
UBS Group
Suvretta Capital Management
Polar Capital Holdings
Siren
OrbiMed Advisors

View all funds holding Apellis Pharmaceuticals